Quantitative analysis of 5HT 2C receptor RNA editing patterns in psychiatric disorders

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 8-13

  O'Neil, Richard T ^a   Emeson, Ronald B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; G protein coupling; RNA editing; RNA processing; Schizophrenia; Suicide

Indexed keywords

ADENOSINE; G PROTEIN COUPLED RECEPTOR; GUANOSINE; INOSINE; SEROTONIN 2C RECEPTOR;

AMINO ACID METABOLISM; ANXIETY; AUTOPSY; BEHAVIOR DISORDER; BRAIN FUNCTION; COMPULSION; DEAMINATION; DEPRESSION; DISEASE CONTROL; DISEASE COURSE; DNA SYNTHESIS; DRUG DEPENDENCE; ENVIRONMENTAL FACTOR; GENE SEQUENCE; HIGH THROUGHPUT SEQUENCING; HUMAN; MENTAL DISEASE; MODULATION; MOLECULAR CLONING; NERVOUS SYSTEM FUNCTION; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REVIEW; RNA EDITING; RNA TRANSLATION; SEQUENCE ANALYSIS; STRESS; SYNAPTIC TRANSMISSION;

HUMANS; MENTAL DISORDERS; RECEPTOR, SEROTONIN, 5-HT2C; RNA EDITING; RNA, MESSENGER; TRANSCRIPTOME;

EID: 81955164856     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.08.026     Document Type: Review

References (96)

1. Abbas A.I., et al. Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method. Nucleic Acids Res. 2010, 38:e118.
2. Abdallah L., et al. Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function. J. Neurosci. 2009, 29:8156-8165.
3. Bahn S., et al. Gene expression profiling in the post-mortem human brain-no cause for dismay. J. Chem. Neuroanat. 2001, 22:79-94.
4. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
5. Basilio C., et al. Synthetic polynucleotides and the amino acid code, V. Proc. Natl. Acad. Sci. U.S.A. 1962, 48:613-616.
6. Bentley D.R., et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008, 456:53-59.
7. Berg K.A., et al. 5-Hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin-dependent mechanisms. Mol. Pharmacol. 1994, 45:826-836.
8. Berg K.A., et al. Interactions between effectors linked to serotonin receptors. Ann. N. Y. Acad. Sci. 1998, 861:111-120.
9. Bockaert J., et al. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006, 326:553-572.
10. Brennan T.J., et al. Sound-induced seizures in serotonin 5-HT2c receptor mutant mice. Nat. Genet. 1997, 16:387-390.
11. Brusa R., et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science 1995, 270:1677-1680.
12. Burns C.M., et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997, 387:303-308.
13. Castle J., et al. Optimization of oligonucleotide arrays and RNA amplification protocols for analysis of transcript structure and alternative splicing. Genome Biol. 2003, 4:R66.
14. Clark T.A., et al. Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol. 2007, 8:R64.
15. Dingledine R., et al. Structural determinants of barium permeation and rectification in non-NMDA glutamate receptor channels. J. Neurosci. 1992, 12:4080-4087.
16. Dracheva S., et al. Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Mol. Psychiatry 2008, 13:1001-1010.
17. Du Y., et al. A-to-I pre-mRNA editing of the serotonin 2C receptor: comparisons among inbred mouse strains. Gene 2006, 382:39-46.
18. Englander M.T., et al. How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J. Neurosci. 2005, 25:648-651.
19. Fagnani M., et al. Functional coordination of alternative splicing in the mammalian central nervous system. Genome Biol. 2007, 8:R108.
20. Fitzgerald L.W., et al. Messenger RNA editing of the human serotonin 5-HT2C receptor. Neuropsychopharmacology 1999, 21:82S-90S.
21. Fletcher P.J., et al. Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. Neuropsychopharmacology 2004, 29:308-318.
22. Gardina P.J., et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006, 7:325.
23. Giorgetti M., Tecott L.H. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol. 2004, 488:1-9.
24. Goldstone A.P. Prader-Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol. Metab. 2004, 15:12-20.
25. Gott J.M., Emeson R.B. Functions and mechanisms of RNA editing. Annu. Rev. Genet. 2000, 34:499-531.
26. Gurevich I., et al. Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission. J. Neurosci. 2002, 22:10529-10532.
27. Gurevich I., et al. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 2002, 34:349-356.
28. Haas B.J., Zody M.C. Advancing RNA-seq analysis. Nat. Biotechnol. 2010, 28:421-423.
29. Hackler E.A., et al. 5-HT(2C) receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice. Neurosci. Res. 2006, 55:96-104.
30. Halford J.C., et al. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67:27-55.
31. Harada K., et al. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur. J. Pharmacol. 2006, 553:171-184.
32. Hogg M., et al. RNA editing by mammalian ADARs. Adv. Genet. 2011, 73:87-120.
33. Hollmann M., et al. Ca2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 1991, 252:851-853.
34. Hoopengardner B., et al. Nervous system targets of RNA editing identified by comparative genomics. Science 2003, 301:832-836.
35. Horvath S., et al. Analyzing schizophrenia by DNA microarrays. Biol. Psychiatry 2011, 69:157-162.
36. Hoyer D., et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994, 46:157-203.
37. Hoyer D., et al. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 2002, 71:533-554.
38. Iwamoto K., Kato T. Effects of cocaine and reserpine administration on RNA editing of rat 5-HT2C receptor estimated by primer extension combined with denaturing high-performance liquid chromatography. Pharmacogenomics J. 2002, 2:335-340.
39. Iwamoto K., Kato T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci. Lett. 2003, 346:169-172.
40. Iwamoto K., Kato T. Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist 2006, 12:349-361.
41. Iwamoto K., et al. Estimating RNA editing efficiency of five editing sites in the serotonin 2C receptor by pyrosequencing. RNA 2005, 11:1596-1603.
42. Jacobs M.M., et al. ADAR1 and ADAR2 expression and editing activity during forebrain development. Dev. Neurosci. 2009, 31:223-237.
43. Jepson J.E., Reenan R.A. RNA editing in regulating gene expression in the brain. Biochim. Biophys. Acta 2008, 1779:459-470.
44. Johnson J.M., et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003, 302:2141-2144.
45. Kawahara Y., et al. Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J. Neurosci. 2008, 28:12834-12844.
46. Kennett G.A., et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 1997, 36:609-620.
47. Kwan T., et al. Genome-wide analysis of transcript isoform variation in humans. Nat. Genet. 2008, 40:225-231.
48. Li J.B., et al. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science 2009, 324:1210-1213.
49. Li M., et al. Widespread RNA and DNA sequence differences in the human transcriptome. Science 2011, 333:53-58.
50. Liu S., et al. A comparison of RNA-seq and high-density exon array for detecting differential gene expression between closely related species. Nucleic Acids Res. 2011, 39:578-588.
51. Lovci M.T., et al. RNA-seq analysis of gene expression and alternative splicing by double-random priming strategy. Methods Mol. Biol. 2011, 729:247-255.
52. Marioni J.C., et al. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008, 18:1509-1517.
53. Marquis K.L., et al. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J. Pharmacol. Exp. Ther. 2007, 320:486-496.
54. Mehta D., et al. Gene expression studies in major depression. Curr. Psychiatry Rep. 2010, 12:135-144.
55. Melcher T., et al. Editing of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR-B pre-mRNA in vitro reveals site-selective adenosine to inosine conversion. J. Biol. Chem. 1995, 270:8566-8570.
56. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21:106S-115S.
57. Mirnics K., Pevsner J. Progress in the use of microarray technology to study the neurobiology of disease. Nat. Neurosci. 2004, 7:434-439.
58. Mirnics K., et al. DNA microarray analysis of postmortem brain tissue. Int. Rev. Neurobiol. 2004, 60:153-181.
59. Morabito M.V., et al. Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome. Neurobiol. Dis. 2010, 39:169-180.
60. Morabito M.V., et al. High-throughput multiplexed transcript analysis yields enhanced resolution of 5-hydroxytryptamine 2C receptor mRNA editing profiles. Mol. Pharmacol. 2010, 77:895-902.
61. Mortazavi A., et al. Mapping and quantifying mammalian transcriptomes by RNA-seq. Nat. Methods 2008, 5:621-628.
62. Nagalakshmi U., et al. RNA-seq: a method for comprehensive transcriptome analysis. Curr. Protoc. Mol. Biol. 2010, 11:1-13. Chapter 4, Unit 4.
63. Nicholls R.D., Knepper J.L. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu. Rev. Genomics Hum. Genet. 2001, 2:153-175.
64. Niswender C.M., et al. Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann. N. Y. Acad. Sci. 1998, 861:38-48.
65. Niswender C.M., et al. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J. Biol. Chem. 1999, 274:9472-9478.
66. Niswender C.M., et al. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology 2001, 24:478-491.
67. Pan Q., et al. Revealing global regulatory features of mammalian alternative splicing using a quantitative microarray platform. Mol. Cell 2004, 16:929-941.
68. Pan Q., et al. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008, 40:1413-1415.
69. Pasqualetti M., et al. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 1999, 92:601-611.
70. Pompeiano M., et al. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res. Mol. Brain Res. 1994, 23:163-178.
71. Rocha B.A., et al. Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J. Neurosci. 2002, 22:10039-10045.
72. Rueter S.M., et al. Glutamate receptor RNA editing in vitro by enzymatic conversion of adenosine to inosine. Science 1995, 267:1491-1494.
73. Rula E.Y., Emeson R.B. Mouse models to elucidate the functional roles of adenosine-to-inosine editing. Methods Enzymol. 2007, 424:333-367.
74. Schaub M., Keller W. RNA editing by adenosine deaminases generates RNA and protein diversity. Biochimie 2002, 84:791-803.
75. Scott H.S., Chrast R. Global transcript expression profiling by Serial Analysis of Gene Expression (SAGE). Genet. Eng. (N Y) 2001, 23:201-219.
76. Seeburg P.H., Hartner J. Regulation of ion channel/neurotransmitter receptor function by RNA editing. Curr. Opin. Neurobiol. 2003, 13:279-283.
77. Sequeira A., Turecki G. Genome wide gene expression studies in mood disorders. OMICS 2006, 10:444-454.
78. Siuciak J.A., et al. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology 2007, 52:279-290.
79. Sodhi M.S., et al. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol. Psychiatry 2001, 6:373-379.
80. Sodhi M.S., et al. A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts. Mol. Pharmacol. 2005, 68:711-719.
81. Somerville E.M., et al. 5-HT(2C) receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. Eur. J. Neurosci. 2007, 25:3115-3124.
82. Sommer B., et al. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 1991, 67:11-19.
83. Tecott L.H., et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995, 374:542-546.
84. Torrey E.F., et al. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr. Res. 2000, 44:151-155.
85. Velculescu V.E., et al. Analysing uncharted transcriptomes with SAGE. Trends Genet. 2000, 16:423-425.
86. Verdoorn T.A., et al. Structural determinants of ion flow through recombinant glutamate receptor channels. Science 1991, 252:1715-1718.
87. Wahlstedt H., et al. Large-scale mRNA sequencing determines global regulation of RNA editing during brain development. Genome Res. 2009, 19:978-986.
88. Wang Q., et al. Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin2C receptors. J. Neurochem. 2000, 74:1290-1300.
89. Wang E.T., et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476.
90. Wang Z., et al. RNA-seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 2009, 10:57-63.
91. Werry T.D., et al. Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J. Neurochem. 2005, 93:1603-1615.
92. Werry T.D., et al. RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function. Pharmacol. Ther. 2008, 119:7-23.
93. Wilhelm B.T., et al. Defining transcribed regions using RNA-seq. Nat. Protoc. 2010, 5:255-266.
94. Yamamoto M., et al. Use of serial analysis of gene expression (SAGE) technology. J. Immunol. Methods 2001, 250:45-66.
95. Yang J.H., et al. Editing of glutamate receptor subunit B pre-mRNA in vitro by site-specific deamination of adenosine. Nature 1995, 374:77-81.
96. Zinshteyn B., Nishikura K. Adenosine-to-inosine RNA editing. Wiley Interdiscip. Rev. Syst. Biol. Med. 2009, 1:202-209.